Welcome to our dedicated page for TFF Pharmaceuticals news (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on TFF Pharmaceuticals stock.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative drug products utilizing their patented Thin Film Freezing (TFF) technology. This groundbreaking technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations. The TFF platform provides numerous advantages, including high absorption and yield, uniform particle size, and a gentle process that preserves the integrity of complex therapeutic components.
Core Business and Products
TFF Pharmaceuticals has two lead drug candidates currently under clinical evaluation: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). These inhaled dry powder drugs are designed to treat lung disorders and organ transplant rejection, respectively.
Recent Achievements and Projects
Recently, TFF Pharmaceuticals announced positive data from their ongoing Phase 2 study of TFF TAC, which is being developed to prevent organ rejection in lung transplant recipients. The study indicates that TFF TAC provides sufficient immunosuppression to prevent rejection at significantly reduced doses compared to oral tacrolimus, potentially reducing the risk of kidney toxicity.
Financial Condition and Partnerships
As of the first quarter of 2024, TFF Pharmaceuticals has secured additional financing to continue advancing their TFF TAC program toward registrational testing. The company is actively collaborating with large pharmaceutical companies, academic institutions, and government partners to expand their pipeline and revolutionize healthcare globally.
Technology and Patents
The TFF technology platform is protected by over 170 patents issued or pending in the U.S. and internationally. This versatile platform can convert vaccines, small and large molecules, and biologics into elegant dry powders, making them ideal for inhalation or topical delivery.
The company’s proprietary TFF process allows for the direct delivery of therapies to target organs such as the lungs, which can improve bioavailability, reduce dosages, and minimize side effects. Laboratory data suggest that the aerodynamic properties of TFF powders can deliver as much as 75% of the dose to the deep lung.
Conclusion
TFF Pharmaceuticals is at the forefront of transforming biopharmaceutical delivery methods with its innovative TFF technology. By developing dry powder formulations that offer enhanced efficacy, safety, and stability, the company is poised to make significant impacts in the treatment of lung disorders and beyond.
TFF Pharmaceuticals, in collaboration with Cleveland Clinic, announced the advancement of multiple multivalent universal influenza vaccines into preclinical testing. Utilizing TFF's Thin Film Freezing technology, these vaccines aim to protect against seasonal and pandemic flu viruses. The preclinical testing decision follows successful formulation testing and stability data on hemagglutinin (HA) antigens with four adjuvants. Funded by NIAID, this work aims to create a universal, shelf-stable, and easy-to-transport vaccine, potentially advancing to human clinical trials. The research targets a vaccine that circumvents cold chain storage needs and improves distribution. TFF received a $2.97M SBIR grant in June 2023 for this project, highlighting its potential efficacy and protection against influenza A viruses.
TFF Pharmaceuticals announced an update on its Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. The trial has accelerated patient enrollment with 10 patients currently enrolled. All 6 patients who completed the 12-week treatment have opted to continue to the safety extension phase. One patient has been on treatment for over a year, and three others for more than six months.
The initial pharmacokinetic (PK) data shows reduced systemic variability with TFF TAC, potentially lowering risks of acute rejection and systemic toxicities. Positive feedback includes reduced headaches and improved wellness. A more detailed clinical update is expected later in the year.
TFF Pharmaceuticals (NASDAQ: TFFP) announced its first quarter 2024 financial results, highlighting significant advances in clinical development. The company raised $6.0 million, supporting the progression of its Tacrolimus Inhalation Powder (TFF TAC) for lung transplant recipients. Recent data from the Phase 2 trial showed TFF TAC's potential in preventing organ rejection with favorable safety outcomes. The company submitted a study plan to the FDA and expects feedback in the second quarter. Financially, TFF Pharmaceuticals reported a net loss of $5.7 million, down from $7.1 million in the previous year. R&D expenses decreased by 12%, and G&A expenses fell by 22%. Cash and equivalents stood at $3.2 million as of March 31, 2024.
TFF Pharmaceuticals, Inc (Nasdaq: TFFP) closed a public offering, raising approximately $4.8 million by selling shares and warrants. The company plans to use the net proceeds for general corporate purposes and working capital.
TFF Pharmaceuticals, Inc. announced a public offering of 1,665,219 shares of common stock and warrants, priced at $2.875 per share, with gross proceeds estimated at $4.8 million. The Company plans to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on May 1, 2024.
TFF Pharmaceuticals has released Phase 2 data from Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. Results show TFF TAC can prevent rejection at lower doses than oral tacrolimus, reducing systemic exposures and toxicities. Gene expression data indicate TFF TAC normalizes rejection-related genes, potentially improving efficacy and safety post-transplant.
FAQ
What is the current stock price of TFF Pharmaceuticals (TFFP)?
What is the market cap of TFF Pharmaceuticals (TFFP)?
What is TFF Pharmaceuticals, Inc.?
What is Thin Film Freezing (TFF) technology?
What are the lead drug candidates of TFF Pharmaceuticals?
What recent achievements has TFF Pharmaceuticals made?
How does TFF technology benefit drug delivery?
How many patents protect TFF Pharmaceuticals' technology?
Who are TFF Pharmaceuticals' partners?
What financial condition is TFF Pharmaceuticals in?
Where can I find more information about TFF Pharmaceuticals?
What are the next steps for TFF Pharmaceuticals' clinical trials?
